Gelesis Holdings (Gelesis Holdings) Days Inventory : 1,065.41 (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Gelesis Holdings Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Gelesis Holdings's Average Total Inventories for the three months ended in Jun. 2023 was $5.81 Mil. Gelesis Holdings's Cost of Goods Sold for the three months ended in Jun. 2023 was $0.50 Mil. Hence, Gelesis Holdings's Days Inventory for the three months ended in Jun. 2023 was 1,065.41.

The historical rank and industry rank for Gelesis Holdings's Days Inventory or its related term are showing as below:

GLSWQ' s Days Inventory Range Over the Past 10 Years
Min: 134.88 Med: 314.29 Max: 493.7
Current: 207.61

During the past 2 years, Gelesis Holdings's highest Days Inventory was 493.70. The lowest was 134.88. And the median was 314.29.

GLSWQ's Days Inventory is not ranked
in the Biotechnology industry.
Industry Median: 194.42 vs GLSWQ: 207.61

Gelesis Holdings's Days Inventory increased from Jun. 2022 (334.58) to Jun. 2023 (1,065.41). It might indicate that Gelesis Holdings's sales slowed down.

Warning Sign:

If a company builds up inventory, it may mean it is having difficulties selling its goods.

Inventory Turnover measures how fast the company turns over its inventory within a year. Gelesis Holdings's Inventory Turnover for the three months ended in Jun. 2023 was 0.09.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Gelesis Holdings's Inventory-to-Revenue for the three months ended in Jun. 2023 was 5.25.

Gelesis Holdings Days Inventory Historical Data

The historical data trend for Gelesis Holdings's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gelesis Holdings Days Inventory Chart

Gelesis Holdings Annual Data

Trend

Dec21

Dec22

Days Inventory

493.70

134.88

Gelesis Holdings Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Days Inventory	Get a 7-Day Free Trial					334.58	469.78	80.97	472.33	1,065.41

Competitive Comparison of Gelesis Holdings's Days Inventory

For the Biotechnology subindustry, Gelesis Holdings's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gelesis Holdings's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gelesis Holdings's Days Inventory distribution charts can be found below:

* The bar in red indicates where Gelesis Holdings's Days Inventory falls into.

Gelesis Holdings Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Gelesis Holdings's Days Inventory for the fiscal year that ended in Dec. 2022 is calculated as

	Days Inventory (A: Dec. 2022 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2021 )	+	Total Inventories (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (13.503	+	6.865)	/	2 )	/	27.558	*	365
=	10.184					/	27.558	*	365
=	134.88

Gelesis Holdings's Days Inventory for the quarter that ended in Jun. 2023 is calculated as:

	Days Inventory (Q: Jun. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Mar. 2023 )	+	Total Inventories (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (5.941	+	5.688)	/	2 )	/	0.498	*	365 / 4
=	5.8145					/	0.498	*	365 / 4
=	1,065.41

Gelesis Holdings (OTCPK:GLSWQ) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Gelesis Holdings's Inventory Turnover for the three months ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0.498	/	5.8145
	=	0.09

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Gelesis Holdings's Inventory to Revenue for the three months ended in Jun. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	5.8145	/	1.107
	=	5.25

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Gelesis Holdings Days Inventory Related Terms

Thank you for viewing the detailed overview of Gelesis Holdings's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Gelesis Holdings (Gelesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSWQ) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

501 Boylston Street, Suite 6102, Boston, MA, USA, 02116

Website

https://www.gelesis.com

Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.